Researchers found that the OMNI® Ultra Surgical System has received FDA clearance for treating primary open-angle glaucoma (POAG) in adults. This innovative device allows for a minimally invasive procedure that combines canaloplasty and trabeculotomy to effectively lower intraocular pressure (IOP) without leaving any implants behind. The OMNI Ultra is designed to improve the efficiency and precision of glaucoma surgeries, which could be a game-changer for those seeking effective treatments to preserve their vision.

This development is particularly significant for individuals diagnosed with POAG, a condition that can lead to irreversible blindness if not managed properly. The OMNI Ultra system addresses all three areas of resistance in the eye’s drainage system through a single microincision, potentially reducing the need for ongoing medication and improving overall eye health. With over 350,000 procedures performed globally using the OMNI platform, this new system promises to enhance treatment outcomes and offer surgeons greater flexibility in managing varying disease severities.

The evidence supporting the OMNI Ultra is based on extensive clinical studies, which have shown meaningful reductions in IOP and medication burden for patients. While the FDA clearance is a significant milestone, the commercial launch is expected in the fourth quarter of 2026, meaning that further real-world data will be gathered as more surgeons begin using this technology. As with any new treatment, it’s essential to stay informed and consult with healthcare professionals about the best options for managing glaucoma.

For more details, visit the original source at GlobeNewswire.